Sinovac Biotech: Clinical trial application for innovative drug GB19 injection approved by the FDA

Sinovac Biotech announcement. Its wholly owned subsidiary, Shenzhen Sinovac Pharmaceutical Co., Ltd., received a notice from the U.S. Food and Drug Administration. The FDA has approved the clinical trial application for GB19 injection, an innovative drug independently developed by Shenzhen Sinovac, allowing clinical trials to be conducted in the United States. The indication is for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments